Info trouvée sur le blog de Korben : "Des scientifiques Israëliens auraient mis au point un vaccin contre le cancer. Oui, un 'vaccin' qui d'après les premiers tests serait super efficace. Mis au point par les scientifiques de Vaxil BioTherapeutics, ce vaccin baptisé ImMucin fait aussi office de médicament et pourrait carrément guérir des personnes déjà atteintes d'un cancer.Alors comment ça marche ? Et bien lorsqu'on a un cancer, notre système immunitaire n'est pas capable de débusquer les cellules cancéreuses et celles-ci, malheureusement, prolifèrent. Le point commun de toutes ces cellules, c'est qu'elles possèdent un marqueur unique appelé le MUC1. Le ImMucin a pour rôle de briefer les lymphocytes T du système immunitaire afin que ces derniers détectent et éliminent les cellules marquées par le MUC1.
Les premiers tests ont été effectués contre la maladie de Kahler, un cancer du sang, avec un taux d'élimination des cellules cancéreuses de 90%. Toujours d'après les scientifiques israéliens de Vaxil, le ImMucin pourrait être utilisé contre d'autres formes de cancers comme celui du sein ou de la prostate. Petite cerise sur le gâteau, ce médicament n'aurait aucun effet secondaire et serait totalement sûr pour l'organisme.
Mais point de précipitation, car il ne faudra pas loin de 6 années de tests avant que ce remède soit accessible à tous. Si tout ceci se révèle aussi efficace que ça en a l'air, ce sera une grande victoire pour la science et un grand soulagement pour tous les gens atteints par cette maladie.
Pour terminer, au fil de mes recherches, je suis aussi tombé sur cette annonce similaire faite par des chercheurs français pour le cancer du poumon. Cocorico !"
Mon commentaire : il faut savoir qu'Israël investit de manière massive dans l'éducation et la recherche (médicale entre autres), contrairement à la France, reine du saupoudrage ... Je fais un peu moins cocorico depuis que j'ai lu ceci ...
Vaxil’s groundbreaking therapeutic vaccine, developed in Israel, could keep about 90 percent of cancers from coming back.
"As the world’s population lives longer than ever, if we don’t succumb to heart disease, strokes or accidents, it is more likely that cancer will get us one way or another. Cancer is tough to fight, as the body learns how to outsmart medical approaches that often kill normal cells while targeting the malignant ones.
In a breakthrough development, the Israeli company Vaxil BioTherapeutics has formulated a therapeutic cancer vaccine, now in clinical trials at Hadassah University Medical Center in Jerusalem. If all goes well, the vaccine could be available about six years down the road, to administer on a regular basis not only to help treat cancer but in order to keep the disease from recurring.
The vaccine is being tested against a type of blood cancer called multiple myeloma. If the substance works as hoped — and it looks like all arrows are pointing that way — its platform technology VaxHit could be applied to 90 percent of all known cancers, including prostate and breast cancer, solid and non-solid tumors.
'In cancer, the body knows something is not quite right but the immune system doesn’t know how to protect itself against the tumor like it does against an infection or virus. This is because cancer cells are the body’s own cells gone wrong,' says Julian Levy, the company’s CFO. 'Coupled with that, a cancer patient has a depressed immune system, caused both by the illness and by the treatment.'
The trick is to activate a compromised immune system to mobilize against the threat.
A vaccine that works like a drug
A traditional vaccine helps the body’s immune system fend off foreign invaders such as bacteria or viruses, and is administered to people who have not yet had the ailment. Therapeutic vaccines, like the one Vaxil has developed, are given to sick people, and work more like a drug.
Vaxil’s lead product, ImMucin, activates the immune system by 'training' T-cells –– the immune cells that protect the body by searching out and destroying cells that display a specific molecule (or marker) called MUC1. MUC1 is typically found only on cancer cells and not on healthy cells. The T-cells don’t attack any cells without MUC1, meaning there are no side effects unlike traditional cancer treatments. More than 90% of different cancers have MUC1 on their cells, which indicates the potential for this vaccine.
'It’s a really big thing,' says Levy, a biotechnology entrepreneur who was formerly CEO for Biokine Therapeutics. 'If you give chemo, apart from the really nasty side effects, what often happens is that cancer becomes immune [to it]. The tumor likes to mutate and develops an ability to hide from the treatment. Our vaccines are also designed to overcome that problem.'
For cancers in an advanced stage, treatments like chemo or surgery to remove a large tumor will still be needed, but if the cancer can be brought down to scale, the body is then able to deal with it, Levy explains. ImMucin is foreseen as a long-term strategy — a shot every few months, with no side effects — to stop the cancer from reoccurring after initial treatments, by ensuring that the patient’s own immune system keeps it under control.
In parallel, the company is also working on a vaccine that treats tuberculosis, a disease that’s increasing worldwide, including in the developed world, and for which the current vaccine is often ineffective and treatment is problematic.
Based in Ness Ziona, Vaxil was founded in 2006 by Dr. Lior Carmon, a biotechnology entrepreneur with a doctorate in immunology from the Weizmann Institute of Science in Rehovot. In June, Vaxil signed a memorandum of understanding to merge its activities into Sheldonco, a company traded on the Tel Aviv Stock Exchange."
By Rivka Borochov
For more info about this incredible vaccine, visit Vaxil on the web at www.vaxilbio.com
http://unitedwithisrael.org/israel-develops-cancer-vaccine/
Articles
Aucun commentaire:
Enregistrer un commentaire